[1] [1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1 201 population-representative studies with 104 million participants[J]. Lancet, 2021, 398(10304):957-980.

[2] [2] Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)[J]. Lancet, 2017, 390(10112):2549-2558.

[3] [3] Olawade DB, Aderinto N, Olatunji G, et al. Advancements and applications of Artificial Intelligence in cardiology: Current trends and future prospects[J]. MICROELECTRON J, 2024, 3:100109.

[4] [4] Mills KT, Stefanescu A, He J. The global epidemiology of hypertension[J]. Nat Rev Nephrol, 2020, 16(4):223-237.

[5] [5] Goorani S, Zangene S, Imig JD. Hypertension: a continuing public healthcare issue[J]. Int J Mol Sci, 2024, 26(1):123.

[6] [6] Bakris GL, Weber MA. Overview of the evolution of hypertension: from ancient Chinese emperors to today[J]. Hypertension, 2024, 81(4):717-726.

[7] [7] Ji H, Xiong J, Yu S, et al. Northern Shanghai Study: cardiovascular risk and its associated factors in the Chinese elderly-a study protocol of a prospective study design[J]. BMJ Open, 2017, 7(3):e013880.

[9] [9] Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial[J]. Lancet, 2022, 400(10367):1927-1937.

[10] [10] Harari YN. Homo Deus: A brief history of tomorrow[M]. New York: HarperCollins, 2017:1-440.

[12] [12] Asgari S, Scalzo F, Kasprowicz M. Pattern recognition in medical decision support[J]. Biomed Res Int, 2019, 2019:6048748.

[13] [13] Schutte AE, Kollias A, Stergiou GS. Blood pressure and its variability: classic and novel measurement techniques[J]. Nat Rev Cardiol, 2022, 19(10):643-654.

[14] [14] Shimbo D, Shah RU, Abdalla M, et al. Transforming hypertension diagnosis and management in the era of artificial intelligence: a 2023 National Heart, Lung, and Blood Institute (NHLBI) workshop report[J]. Hypertension, 2025, 82(1):36-45.

[15] [15] Kario K, Williams B, Tomitani N, et al. Innovations in blood pressure measurement and reporting technology: International Society of Hypertension position paper endorsed by the World Hypertension League, European Society of Hypertension, Asian Pacific Society of Hypertension, and Latin American Society of Hypertension[J]. J Hypertens, 2024, 42(11):1874-1888.

[16] [16] Kario K, Hoshide S, Mogi M. Digital hypertension 2023: concept, hypothesis, and new technology[J]. Hypertens Res, 2022, 45(10):1529-1530.

[17] [17] Visco V, Izzo C, Mancusi C, et al. Artificial intelligence in hypertension management: an ace up your sleeve[J]. J Cardiovasc Dev Dis, 2023, 10(2):74.

[18] [18] Yang E, Schutte AE, Stergiou G, et al. Cuffless blood pressure measurement devices-international perspectives on accuracy and clinical use: a narrative review[J]. JAMA Cardiol, 2025, 10(6):624-631.

[19] [19] Li W, Gnanenthiran SR, Schutte AE, et al. Blood pressure time at target and its prognostic value for cardiovascular outcomes: a scoping review[J]. Hypertens Res, 2024, 47(9):2337-2350.

[20] [20] Li M, Zhao S, Yu S, et al. Association between systolic blood pressure time in target range indices and adverse cardiovascular outcomes[J]. JACC Adv, 2024, 3(11):101350.

[22] [22] Cho JS, Park JH. Application of artificial intelligence in hypertension[J]. Clin Hypertens, 2024, 30(1):11.

[23] [23] Diao X, Huo Y, Yan Z, et al. An application of machine learning to etiological diagnosis of secondary hypertension: retrospective study using electronic medical records[J]. JMIR Med Inform, 2021, 9(1):e19739.

[24] [24] Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial[J]. JAMA, 2008, 299(24):2857-2867.

[25] [25] Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial[J]. JAMA, 2013, 310(1):46-56.

[26] [26] McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial[J]. Lancet, 2018, 391(10124):949-959.

[27] [27] Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial[J]. Arch Intern Med, 2011, 171(13):1173-1180.

[28] [28] McManus RJ, Mant J, Bray EP, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial[J]. Lancet, 2010, 376(9736):163-172.

[29] [29] McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial[J]. JAMA, 2014, 312(8):799-808.

[30] [30] Li Y, Maimaitiaili R, Zhang Y, et al. Simplified regimen for the management of hypertension with telemedicine and blood pressure self-monitoring (SIMPLE): study protocol for a randomised controlled trial[J]. BMJ Open, 2022, 12(3):e049162.

[31] [31] Kario K, Nomura A, Harada N, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial[J]. Eur Heart J, 2021, 42(40):4111-4122.